Speakers
Peter De Veene, MD
GQPPV, MSD Belgium, Belgium
Peter got his medical degree from the Catholic University of Leuven in Belgium and until the end of 2003, Peter practised as a General Practitioner in the UK. In 2004, he joined Roche as a drug safety physician in the local organisation. Taking up roles with increasing responsibility, Peter was appointed Qualified Person for Pharmacovigilance for Roche in 2011. He left Roche at the end of 2014 to take a role at Daichii Sankyo and moved on to be the Head of Global Drug Safety & QPPV for Grunenthal. Peter has extensive experience in pre-approval and post-marketing pharmacovigilance.
Elspeth McIntosh, MBA, RN
Director, Castle Pharmacovigilance Ltd, United Kingdom
Elspeth McIntosh began her career in the pharmaceutical industry in 1993, initially working in clinical research, before moving into Pharmacovigilance. She has extensive experience of all aspects of pharmacovigilance and has been a small company QPPV since 1999, dealing with innovative, generic and biotech/biological products. Elspeth set up Castle Pharmacovigilance in 2009 and post Brexit she is a UK QPPV and UK National Contact Person for several small pharma companies and provides general PV support to a wide range of pharma companies.
Margaret Anne Walters
Deputy EU Qualified Person for Pharmacovigilance, Merck, Sharp & Dohme Ltd, United Kingdom
With 10 years in research and >30 in safety, Margaret is currently the Deputy EU Qualified Person for Pharmacovigilance at MSD Ltd. Activities include input to the EFPIA PV EWG, ICH, MedDRA (pre-ICH), the EMA EudraVigilance Steering Committee and the EWG, plus authoring papers on parasitology and drug safety
Michael Richardson, MD, FFPM, FRCP
Senior Vice President, WorldWide Patient Safety , Bristol-Myers Squibb, United Kingdom
Michael Richardson has many years of global management experience in research based life Sciences companies. He has worked in major multinational companies’ across the globe both at a Regional management level and heading up Research and Development in Asia. Currently Head of Bristol Myers Squibb’s Pharmacovigilance Function. Prior to this role he headed BMS and Eli Lilly’s Development and Medical Organization across Asia Pacific. Before joining Lilly he worked in a joint venture in Japan, Fujisawa-Fisons setting up their development and quality control organisations and prior to that with Organon laboratories in the UK as Medical Director.
Brian Edwards, DrMed
Vice President, International Society of Pharmacovigilance, United Kingdom
After his training in hospital medicine and clinical research for 14 years, Dr. Edwards joined the UK Medicines Control Agency (MHRA) in 1994 where he had various responsibilities as a pharmacovigilance assessor. In 1999 he joined Parexel to become Senior Medical Director before joining J&J as a deputy QPPV in 2005. In addition he is Director of ISoP Secretariat Ltd, ISoP Board Member and VP in the Alliance Clinical Research Excellence and Safety (ACRES) . He chairs the unique Pharmaceutical ergonomics & human Factors Group in the UK. After 14 years at NDA Regulatory Science Ltd, he has his own pharmacovigilance consultancy Husoteria Ltd
Barbara De Bernardi, MD
EUQPPV Vice President - Head of Global QPPV Office, Pfizer S.r.l., Italy
Vicki Edwards, RPh
Vice President, Pharmacovigilance Excellence and International QPPV, Abbvie, United Kingdom
Vicki, a qualified pharmacist, began her career in hospital pharmacy and later specialized in Drug Information Services, setting up Kuwait's first National Drug Information Centre. After returning to the UK and spending four years in community pharmacy, she transitioned to pharmacovigilance, joining Abbott as EU QPPV in 2005. She stepped down as AbbVie EU QPPV in 2018 due to Brexit. Now, as Head of PV Excellence and International QPPV, Vicki oversees the QPPV Office, Global Safety Compliance, and Risk Management. She is passionate about pharmacovigilance and developing teams.
Winrich Rauschning, DrMed, MD, MBA
QPPV, Biolitec Pharma, Germany
Doris Irene Stenver, MD, MPA
Independent Pharmacovigilance Adviser, Unique Advice, Denmark
Doris Stenver is the founder of Unique Advice and she is specialised in internal medicine and has a master degree in public administration. She is former Chief Medical Officer at the Danish Medicines Agency and former member of the EU Pharmacovigilance Risk Assessment Committee (PRAC). Her regulatory experience comprises all aspects of pharmacovigilance, including scientific evaluation of drug safety issues, development of risk management strategies, policies and guidelines, provision of scientific advice to the pharmaceutical industry, and communication to health care professionals and the public.
Representative Invited
MSD
Francois Domergue
EV Auditable Requirement Project Manager, Business Data and Analytics Department, European Medicines Agency, Netherlands
After studies in clinical research and development, specialising in Clinical data management, Francois worked for pharmaceutical companies in various position in clinical data management. He joined the European Medicines Agency in 2009 where he works in the Data Standardisation and Analytics service of Information Management Division. He is the project manager of the EudraVigilance Auditable Requirements project, set-up to complete the implementation of the new Pharmacovigilance legislation and to deliver the new EudraVigilance system. He is also supporting all activities related to the data management and analysis of the EudraVigilance (EV) system in particular using the EudraVigilance Data Analysis System (EVDAS) and SAS.
Mick Foy
Director of Delivery, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Mick Foy has been with the MHRA for more than 35 years, he is a member of the MHRA’s Executive Committee and has recently been appointed Director of Delivery . Amongst his responsibilities is to drive initiatives to introduce new and improved services to stakeholders. Mick is SRO for the SafetyConnect and RegulatoryConnect programmes. He also leads MHRA efforts to build PV capabilities in other countries particularly low and middle income countries as part of a global initiative with the Bill and Melinda Gates Foundation.
Nick Halsey
Scientific Administrator, European Medicines Agency, Netherlands
Main roles and responsibilities are with the implementation of the EudraVigilance database and international standardisation development through involvement with ICH, ISO and HL7. This also involves providing technical and practical advice to Marketing Authorisation Holders, National Competent Authorities and Sponsors of Clinical Trials on how to implement IT systems to submit data on Adverse Drug Reaction reports electronically to the EudraVigilance database.
Esteban Herrero-Martinez, PhD
Director Regulatory Policy and Intelligence, AbbVie, United Kingdom
Esteban has worked in both academia and industry in a range of roles including academic research, drug discovery, pharmacovigilance and regulatory policy. Before joining AbbVie, Esteban was Director of Regulatory Intelligence and Policy at Daiichi Sankyo Development Ltd, lead for Pharmacovigilance & Regulatory Affairs at the Association of the British Pharmaceutical Industry (ABPI) as well as working in pharmacovigilance for P&G Pharmaceuticals and drug discovery for Novartis. He holds a Biochemistry BSc from Warwick University, PhD in virology from University College London, and has worked as a postdoctoral researcher at Imperial College London
Barry Mulchrone
Senior Director, Marketed Product Safety Services, Lifecycle Safety, IQVIA, Ireland
Anna Pavlou
Legal Counsel, Galderma, Belgium
Agnès Saint-Raymond, DrMed
Head of Division International Affairs, European Medicines Agency, Netherlands
Dr Saint-Raymond is a French paediatrician. In 1995, she joined the French Medicines Agency, and in 2000 she joined the EMA where she was the Head of Special Areas (Paediatrics, Orphan Drugs, Scientific Advice, SME Office and Scientific Projects). She implemented the European Orphan Drug Regulation then the Paediatric Regulation. She has been an expert for the European Commission, the European Developing Countries Trial Partnership, the Canadian Council of Academies, and the US National Academies of Science, Engineering and Medicine, a member of the UN Commission on Life-Saving Commodities for women and Children and Associate Prof of Paediatrics at Tor Vergata University Rome.
Saad Shakir, DrMed, MD, FFPM, FISPE, FRCP
Director, Drug Safety Research Unit, United Kingdom
Saad Shakir is a pharmacoepidemiologist and drug safety physician. He has worked in the fields of pharmacovigilance, pharmacoepidemiology and risk management for 30 years, initially at the UK Regulatory Authority, then the international pharmaceutical industry and as the Director of the Drug Safety Research Unit (DSRU) in Southampton. The DSRU is a service provider and associate department of the University of Portsmouth. At the DSRU Saad leads a research team with an active programme for monitoring and studying the safety of medicines in populations. He has led many important drug safety studies and has worked and advised on many drug safety issues including product withdrawals, major restrictions and important safety hazards.
Willemijn van der Spuij, MSc
Executive Director, WorldWide Patient Safety International, Europe, Switzerland
Willemijn is the Executive Director Europe in the WorldWide Patient Safety Organisation in Bristol Myers Squibb. She is responsible for Patient Safety in the European region, including the Balkans, Baltics and distributor markets. Prior to this role she was responsible for the European markets, PV Intelligence & International Operations including the PSMF as well as Training and Outsourcing activities. Willemijn holds a Nursing Degree from the Netherlands, a BA (Hons) in Sociology from Goldsmiths college, University of London, UK and an MSc in Pharmacovigilance from the University of Hertfordshire, UK. Willemijn is co-chair of the EFPIA Pharmacovigilance Expert Working Group and Chair of the EFPIA International Pharmacovigilance Group.
Sue Rees, MS
Director , Sue Rees Consultancy Ltd, United Kingdom
Sue is a former EU QPPV and established expert in pharmacovigilance in Europe, with over 30 years’ pharmaceutical industry experience across a number of organisations including GSK, AstraZeneca and Amgen and served on the EFPIA PV Expert Group for 10 years. As an independent consultant, Sue now shares her knowledge and expertise with organisations through interim leadership, consultancy projects and training. Sue holds a BSc (Hons) in Biochemistry and MSc in Immunology and is a Senior Lecturer at the University of Hertfordshire for the post graduate Pharmacovigilance Master’s degree course.
Kiernan Trevett, MSc
Quality Policy Lead, Genentech, A Member of the Roche Group, United States
Kiernan joined Roche as a Principal Quality Lead focussing on pharmacovigilance quality assurance strategies. Previously, she worked as a GPvP Inspector at the MHRA for 1O years, with her most recent role being Expert GPvP Inspector. She contributed to the development of the EU GVP, had a role in the training of GPvP Inspectors in other EU Member States and contributed significantly to the MHRA’s preparedness work in relation to the UK’s withdrawal from the EU. Before joining the MHRA, Kiernan worked as a certified Quality Assurance auditor for a central laboratory that provided services for Phase I-III pharmaceutical clinical trials. Kiernan has a Master of Biomedical Sciences degree from the University of Southampton.
June Raine, MD, MSc, FRCP
Chief Executive, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Dr June Raine DBE is CEO of the Medicines and Healthcare products Regulatory Agency. She trained in medicine in Oxford after completing a master’s degree by research in Pharmacology. Her interest in drug safety led to a career in medicines regulation which has spanned a number of roles in assessment, management and strategic development within the UK national authority. She was elected in 2012 as the first chair of the European Pharmacovigilance Risk Assessment Committee and until 2023 was co-Chair of the WHO Advisory Committee on Safety of Medicinal Products. Her special interests are in monitoring the outcomes of regulatory action, risk communication and patient involvement in the regulatory process.
Sabine Straus, MD, PhD, MSc
Former PRAC Chair, Medicines Evaluation Board (MEB), Netherlands
Dr. Sabine Straus has been with the Medicines Evaluation Board (MEB) in the Netherlands since 1997, where she started as an Assessor Pharmacovigilance. Prior to working at the MEB she held different positions in the pharmaceutical industry, her last job as Medical Director at Searle Monsanto in the Netherlands. She was the Dutch member in the Pharmacovigilance Risk Assessment Committee (PRAC) from 2012 till 2018 and acted as PRAC chair from July 2018 till July 2024. She also holds a position as associate professor at the Erasmus Medical Center, department of Medical Informatics in Rotterdam. Her main research focus is on additional risk minimisation, pregnancy prevention programs, biologicals, signal detection and signal management.
Magnus Ysander, MD
EU & UK QPPV & Head Pharmacovigilance Excellence, AstraZeneca, Sweden
Magnus Ysander is the EU and UK QPPV for the AstraZeneca group of companies since 2015. From 2022 he also has the same role for Alexion. Based in Gothenburg, Sweden he joined the company in 2002 and have had several specialist, oversight and line managerial roles within the global AstraZeneca pharmacovigilance organisation. Magnus is a MD and has previously worked as a certified Orthopedic Surgeon. He is a member of EFPIA Pharmacovigilance Expert Group and the Program Committee for the DIA QPPV Forum.
Emil Andrei Cochino, MD, MHS
Scientific Senior Specialist (Risk Management), European Medicines Agency, Netherlands
Dr Emil Andrei Cochino is a Specialist in Public Health and Health Services Management. He has been a scientific officer at EMA from 2009, and is working in the Human Medicines Department as a Scientific Senior Specialist (Risk Management), where he is responsible for peer-reviewing risk management plans for Advanced Therapy Medicinal Products. Furthermore, he is overseeing the revision 3 update of GVP Module V – Risk Management Systems and is coordinating the Agency’s transparency efforts for RMPs.
Leen Verbert
PV QA & Training Director, GlaxoSmithKline Biologicals, Belgium
Nuria Semis-Costa, MSc
Scientific Specialist (Risk Management), European Medicines Agency, Netherlands
Núria Semis-Costa is a biochemist (Universitat Autònoma de Barcelona) with a MSc in Pharmacovigilance (Universitat de Barcelona). After working in the industry in the field of blood products, she joined the EMA as a Risk Management Specialist in 2015, where she works in the areas of rheumatology, immunology and advanced therapies. Núria is also involved in initiatives related to risk management of biosimilars and medicines in pregnancy, the maintenance of the RMP template and the update of GVP XVI.
¿Tiene una cuenta?